Global burden of lung cancer in 2022 and projections to 2050: Incidence and mortality estimates from GLOBOCAN
- PMID: 39536404
- DOI: 10.1016/j.canep.2024.102693
Global burden of lung cancer in 2022 and projections to 2050: Incidence and mortality estimates from GLOBOCAN
Abstract
Background: Lung cancer continues to pose a serious global public health challenge. Timely evidence on the global epidemiological profile of the disease is crucial to facilitate the implementation to lung cancer control efforts. This study provides updated global estimates for lung cancer incidence and mortality in 2022, along with projections for new cases and deaths up to 2050.
Methods: In the population-based study, we extracted data about lung cancer new cases and deaths from GLOBOCAN 2022 database across 185 countries or territories. We analyzed age-standardized rates by sex, country, region, and human development index (HDI). Projected new cases and deaths for 2050 were estimated using global demographic projections.
Results: In 2022, lung cancer stood as the most frequently diagnosed cancer and the primary cause of cancer-related deaths on a global scale with approximately 2.48 million new cases and 1.8 million deaths, respectively. The incidence and mortality rates of lung cancer exhibited disparities in sex and world regions. Furthermore, incidence and mortality rates increasing as HDI increased. If the incidence and mortality rates remain stable as in 2022, the burden of lung cancer is projected to increase to 4·62 million new cases and 3·55 million deaths by 2050.
Conclusions: Lung cancer is the predominant form of cancer and the foremost contributor to cancer-related mortality in 2022 with notable geographical, sex, and socioeconomic disparities.
Keywords: Disparities; GLOBOCAN; Global health; Lung cancer burden; Timely evidence.
Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Burden of 30 cancers among men: Global statistics in 2022 and projections for 2050 using population-based estimates.Cancer. 2024 Nov 1;130(21):3708-3723. doi: 10.1002/cncr.35458. Epub 2024 Aug 12. Cancer. 2024. PMID: 39129420
-
Projected epidemiological trends and burden of liver cancer by 2040 based on GBD, CI5plus, and WHO data.Sci Rep. 2024 Nov 15;14(1):28131. doi: 10.1038/s41598-024-77658-2. Sci Rep. 2024. PMID: 39548154 Free PMC article.
-
Mapping of global, regional and national incidence, mortality and mortality-to-incidence ratio of lung cancer in 2020 and 2050.Int J Clin Oncol. 2022 Apr;27(4):665-675. doi: 10.1007/s10147-021-02108-2. Epub 2022 Jan 12. Int J Clin Oncol. 2022. PMID: 35020103 Free PMC article.
-
The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040: New Estimates From GLOBOCAN 2020.Gastroenterology. 2022 Sep;163(3):649-658.e2. doi: 10.1053/j.gastro.2022.05.054. Epub 2022 Jun 4. Gastroenterology. 2022. PMID: 35671803 Review.
-
Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021.Lancet Infect Dis. 2024 Sep;24(9):974-1002. doi: 10.1016/S1473-3099(24)00176-2. Epub 2024 Apr 15. Lancet Infect Dis. 2024. PMID: 38636536 Free PMC article.
Cited by
-
New Therapeutic Targets TIGIT, LAG-3 and TIM-3 in the Treatment of Advanced, Non-Small-Cell Lung Cancer.Int J Mol Sci. 2025 Apr 25;26(9):4096. doi: 10.3390/ijms26094096. Int J Mol Sci. 2025. PMID: 40362333 Free PMC article. Review.
-
Targeting DNA Damage Response-Mediated Resistance in Non-Small Cell Lung Cancer: From Mechanistic Insights to Drug Development.Curr Oncol. 2025 Jun 23;32(7):367. doi: 10.3390/curroncol32070367. Curr Oncol. 2025. PMID: 40710178 Free PMC article. Review.
-
Targeting cell signaling pathway ALKBH5/Beclin1/ULK1 in lung cancer by 5-flurouracil- loaded P (AAm/SA) nanogel in rats.Apoptosis. 2025 Jun;30(5-6):1628-1644. doi: 10.1007/s10495-025-02102-3. Epub 2025 May 1. Apoptosis. 2025. PMID: 40310576
-
Systematic review on the technology's role in supporting lung cancer patients in the treatment journey.NPJ Digit Med. 2025 Aug 13;8(1):516. doi: 10.1038/s41746-025-01913-7. NPJ Digit Med. 2025. PMID: 40796947 Free PMC article.
-
Influence of migrasome-associated long noncoding RNAs on the immune microenvironment and prognosis in lung adenocarcinoma.Discov Oncol. 2025 Jun 20;16(1):1168. doi: 10.1007/s12672-025-03000-5. Discov Oncol. 2025. PMID: 40542304 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical